Oral antiretroviral therapy (ART) has transformed HIV care, enabling durable virologic suppression and substantially reducing HIV-related morbidity and mortality. However, maintaining virologic suppression requires consistent adherence. In an interview with MIMS Doctor, Dr Thomas Chik, Specialist in Infectious Disease in Hong Kong, discussed how people living with HIV (PLHIV) who achieve HIV RNA <50 copies/mL with oral therapy can be switched early to long-acting cabotegravir plus rilpivirine (CAB + RPV LA), which improves adherence. This is suitable for a range of PLHIV, including those who are new to ART.
Limitations of daily oral ART
“ART is a lifelong treatment. Although current oral therapies are highly effective, adherence to daily regimens can be challenging for several reasons, including concerns about disclosure to others, social stigma, daily reminder of one’s HIV status, and difficulty remembering to take medication,” said Chik. “Lifestyle factors, such as shift work, frequent travel across time zones and irregular schedules, particularly among younger individuals with busy social calendars, can also make daily medication taking somewhat burdensome.” [Clin Infect Dis 2023;76:1646-1654]
“Suboptimal adherence may further lead to treatment interruption, which is associated with viral rebound, increased transmission risk, morbidity, and mortality. Therefore, many patients and healthcare providers welcome long-acting treatments with less frequent dosing,” Chik added.
Switching from oral ART to CAB + RPV LA: Noninferior virologic suppression
CAB + RPV LA is the first complete two-drug injectable regimen, consisting of an HIV-1 integrase strand transfer inhibitor (INSTI) and an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), which is administered every 2 months (Q2M) and is indicated for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL). Phase III and IIIb studies have demonstrated durable maintenance of viral load (VL) <50 copies/mL with CAB + RPV LA, with low rates of virologic failure that are comparable to those observed with standard oral regimens.
In the open-label, phase III FLAIR study (n=566), ART-naïve participants initially received oral induction therapy with dolutegravir, abacavir and lamivudine. At week 16, participants with HIV-1 RNA <50 copies/mL were randomized to receive either intramuscular CAB + RPV Q4W following ≥4 weeks of oral CAB + RPV, or to continue standard oral therapy. At week 96, 3 percent of participants in each arm had HIV-1 RNA levels of ≥50 copies/mL (adjusted difference, 0.0; 95 percent confidence interval, -2.9 to 2.9), demonstrating noninferiority of CAB + RPV LA to continued oral therapy, which was sustained over nearly 2 years. [Lancet HIV 2021;8:e185-e196]
The phase IIIb ATLAS-2M study subsequently evaluated an extended dosing interval. At week 152, CAB + RPV LA administered Q8W was noninferior to the Q4W regimen in 1,045 participants, supporting durable maintenance of VL <50 copies/mL with less frequent administration. [Clin Infect Dis 2023;76:1646-1654]
VOLITION: Enabling early switch to Q2M dosing
VOLITION was a prospective, nonrandomized, open-label, phase IIIb implementation effectiveness study that enrolled 171 ART-naïve adults with a baseline HIV-1 RNA level of ≥1,000 copies/mL. Participants initially received oral dolutegravir/lamivudine; those who attained HIV-1 RNA ≤50 copies/mL at any point between weeks 4 and 16 could either continue DTG/3TC or switch to CAB + RPV LA Q2M at day-of-choice (DoC) visit. Of eligible patients, 129 chose to switch to CAB + RPV LA Q2M. (Figure 1) [Rolle C-P, et al, CROI 2026]

“At month 11, approximately 90 percent of participants who switched to CAB + RPV LA remained virologically suppressed [HIV-1 RNA <50 copies/mL] in both the modified snapshot [88 percent] and the observed [95 percent] analyses. These high viral suppression rates are consistent with the durable efficacy demonstrated in the pivotal phase III/IIIb FLAIR and ATLAS-2M trials, in which CAB + RPV LA provided virologic control that was noninferior to continued daily oral ART. This efficacy is also broadly comparable with outcomes reported for first-line oral ART in real-world studies,” Chik highlighted. “VOLITION showed that switching may be feasible as early as 4 weeks after achieving VL <50 copies/mL. This is particularly notable because, previously, people could switch only after 3–6 months of oral therapy.” (Figure 2) [Rolle C-P, et al, CROI 2026; AIDS Res Ther 2025;22:91]

A preferred option with high patient satisfaction
“Although VOLITION was a nonrandomized study and may have been subject to selection bias, its findings reflect real-world treatment decisions. Of the participants offered the option to switch to the LA regimen, 85 percent chose to do so,” said Chik. The most cited reasons for switching were avoiding missed doses (80 percent), greater convenience when travelling (68 percent), and better alignment with their lifestyle (64 percent). [Rolle C-P, et al, CROI 2026]
At month 11, 89 percent indicated that they planned to continue CAB + RPV LA after completing the study. When asked about the perceived advantages of having the option to switch to CAB + RPV LA, participants most frequently cited better fit with their lives (76 percent), greater freedom to travel (71 percent), and increased autonomy in managing their treatment (63 percent). [Rolle C-P, et al, CROI 2026]
After DoC visit, treatment satisfaction with CAB + RPV LA improved by 4.5 points on the HIV Treatment Satisfaction Questionnaire by month 11, suggesting that satisfaction increases with continued use. [Rolle C-P, et al, CROI 2026] “Satisfaction often reflects treatment efficacy and supports adherence. It can also strengthen the doctor–patient relationship,” Chik commented.
CAB + RPV LA is generally well tolerated. In VOLITION, 51 percent of participants had a drug-related adverse event (AE), the majority of which were injection-site reactions (ISRs; 49 percent) of grade 1 or 2 (98 percent), with a median duration of 3 days. There were no drug-related serious AEs and no AEs leading to withdrawal.
“Injection-site reactions, including pain, nodules and erythema, are most common during the first few injections. Fewer patients report these side effects over time. Most patients appreciate the regimen’s convenience and, in my experience, requests to switch back to oral therapy are uncommon,” shared Chik.
Practical considerations for switching from oral to LA therapy
“Once HIV is diagnosed, clinicians should assess each individual’s lifestyle and preferences and confirm that they are comfortable with injections. We explain the course of HIV infection and the need for oral therapy for minimizing the viral load before switching to an LA injectable. This may encourage PLHIV to adhere to the oral induction phase and enable an earlier switch,” Chik noted.
“Some PLHIV may not be suitable candidates for CAB + RPV LA. For example, concomitant use of rifampicin for tuberculosis is contraindicated because of drug–drug interactions. PLHIV with hepatitis B coinfection may be better suited to tenofovir-based ART,” Chik noted. “Although some clinicians are concerned about bleeding at injection sites in PLHIV on anticoagulants, intramuscular injections are still feasible with proper technique and prolonged compression [eg, for 15–30 minutes].” [Rekambys Hong Kong Prescribing Information]
“Obesity was historically a concern for LA injectables. Using a longer needle to ensure drug delivery into the muscle should address this issue. LA injectables can remain an option for people with metabolic syndrome, provided they are monitored closely,” Chik added.
Despite its convenience and established efficacy, wider implementation of early switching to CAB + RPV LA after reaching HIV RNA <50 copies/mL will require careful management of practical challenges in Hong Kong. “There can be delays of up to a few weeks before obtaining the VL result, depending on the resource availability and laboratory arrangement. This process can be hastened in the private sector,” said Chik.
“Successful adoption of this early-switch strategy relies on clinic capacity, pharmacy coordination and specialist nurse training to manage injection schedules and educate patients,” noted Chik. “If the logistics allow, I would be confident switching patients at 4 weeks, provided their viral load is <50 copies/mL.”
